A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio, Inc
Atavistik Bio, Inc
University of Pittsburgh
Replimune Inc.
Duke University
AstraZeneca
AstraZeneca
M.D. Anderson Cancer Center
University Health Network, Toronto
Tolmar Inc.
King's College London
Eli Lilly and Company
Novartis
Brigham and Women's Hospital
The Christie NHS Foundation Trust
AstraZeneca
University of Colorado, Denver
Eli Lilly and Company
M.D. Anderson Cancer Center
AstraZeneca
SOLTI Breast Cancer Research Group
Proton Collaborative Group
Exelixis
AbbVie
Milton S. Hershey Medical Center
Bristol-Myers Squibb
University College, London
University of Chicago
Memorial Sloan Kettering Cancer Center
AbbVie
Tempus AI
N.N. Petrov National Medical Research Center of Oncology
University of Coimbra
City of Hope Medical Center
Alliance for Clinical Trials in Oncology
Duke University
Karolinska University Hospital
Carisma Therapeutics Inc
Actuate Therapeutics Inc.
Salubris Biotherapeutics Inc
Hospital Sirio-Libanes
Odense University Hospital